Balyasny Asset Management LLC Adaptimmune Therapeutics PLC Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $907,945 - $1.47 Million	-259,413 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $892,380 - $1.65 Million	259,413 New	259,413 $1.34 Million
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $2.06 Million - $3.44 Million	-567,401 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $1.56 Million - $5.87 Million	-414,599 Reduced 42.22%	567,401 $3.26 Million
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $1.37 Million - $2.25 Million	165,716 Added 20.3%	982,000 $13.3 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $1.36 Million - $1.8 Million	-130,784 Reduced 13.81%	816,284 $9.69 Million
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $1.59 Million - $2.59 Million	224,078 Added 30.99%	947,068 $10.6 Million
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $822,909 - $1.08 Million	123,190 Added 20.54%	722,990 $4.83 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $2.96 Million - $5.36 Million	599,800	599,800 $4.91 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $101M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.